Patent details

EP2991999 Title: DAPAGLIFLOZIN LACTOSE CO-CRYSTAL

Basic Information

Publication number:
EP2991999
PCT Application Number:
IL2013051048
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP138833546
PCT Publication Number:
WO2014178040
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
DAPAGLIFLOZIN LACTOSE CO-CRYSTAL
French Title of Invention:
CO-CRISTAL DE DAPAGLIFLOZINE ET DE LACTOSE
German Title of Invention:
DAPAGLIFLOZIN LAKTOSE CO-KRISTAL
SPC Number:

Dates

Filing date:
23/12/2013
Grant date:
08/05/2019
EP Publication Date:
09/03/2016
PCT Publication Date:
06/11/2014
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
08/05/2019
EP B1 Publication Date:
08/05/2019
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
23/12/2019
Expiration date:
23/12/2033
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
01/05/2019
 
 

Name:
Mapi Pharma Limited
Address:
16 Einstein Street Weizmann Science Park P.O. Box 4113, 74140 Ness Ziona, Israel (IL)

Inventor

1

Name:
MAROM, Ehud
Address:
Israel (IL)

2

Name:
RUBNOV, Shai
Address:
Israel (IL)

Priority

Priority Number:
201361816809 P
Priority Date:
29/04/2013
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/70; A61P 3/10; C07H 7/04;

Publication

European Patent Bulletin

Issue number:
201919
Publication date:
08/05/2019
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages